Aptamers as promising molecular recognition elements for diagnostics and therapeutics in the central nervous system

Nucleic Acid Therapeutics

Volumn 24, Issue 6, 2014, Pages 388-404

  McConnell, Erin M ^a   Holahan, Matthew R ^a   Derosa, Maria C ^a  

^a CARLETON UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; DOPAMINE; NEUROTOXIN; NEUROTRANSMITTER; OLIGONUCLEOTIDE; TRANSFERRIN RECEPTOR;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHEMICAL MODIFICATION; DEMYELINATING DISEASE; DRUG DELIVERY SYSTEM; DRUG RECEPTOR BINDING; DRUG TARGETING; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNOGENICITY; MIGRAINE; MOLECULAR RECOGNITION; NONHUMAN; PARKINSON DISEASE; PRION DISEASE; PROTEIN AGGREGATION; SCHIZOPHRENIA; SPINAL CORD INJURY; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR DISORDERS; DEMYELINATING DISEASES; DRUG EFFECTS; GENETICS; NERVOUS SYSTEM DISEASES; PROTEIN AGGREGATION, PATHOLOGICAL; SPINAL CORD INJURIES;

APTAMERS, NUCLEOTIDE; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR DISORDERS; DEMYELINATING DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; NERVOUS SYSTEM DISEASES; PROTEIN AGGREGATION, PATHOLOGICAL; SPINAL CORD INJURIES;

EID: 84915798214     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2014.0492     Document Type: Article

References (165)

1. McKeague M and MC DeRosa. (2012). Challenges and opportunities for small molecule aptamer development. J Nucleic Acids 2012:748913.
2. Ye M, J Hu, M Peng, J Liu, J Liu, H Liu, X Zhao and W Tan. (2012). Generating aptamers by cell-SELEX for applications in molecular medicine. Int J Mol Sci 13: 3341-3353.
3. Cruz-Toledo J, M McKeague, X Zhang, A Giamberardino, E McConnell, T Francis, MC DeRosa and M Dumontier. (2012). Aptamer base: a collaborative knowledge base to describe aptamers and SELEX experiments. Database (Oxford) 2012:bas006.
4. Tuerk C and L Gold. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505-510.
5. Ellington AD and JW Szostak. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-822.
6. Robertson DL and GF Joyce. (1990). Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA. Nature 344:467-468.
7. Jing M and MT Bowser. (2011). Methods for measuring aptamer-protein equilibria: a review. Anal Chim Acta 686: 9-18.
8. Bruno JG. (2013). A review of therapeutic aptamer conjugates with emphasis on new approaches. Pharmaceuticals (Basel) 6:340-357.
9. Wang T and J Ray. (2012). Aptamer-based molecular imaging. Protein Cell 3:739-754.
10. Lee JH, MV Yigit, D Mazumdar and Y Lu. (2010). Molecular diagnostics and drug delivery agents based on aptamernanomaterial conjugates. Adv Drug Deliv Rev 62: 592-605.
11. Bunka DHJ, O Platonova and PG Stockley. (2010). Development of aptamer therapeutics. Curr Opin Pharmacol 10:557-562.
12. Tolle F and G Mayer. (2013). Dressed for success- applying chemistry to modulate aptamer functionality. Chem Sci 4:60-67.
13. Yang Y, X Ren, HJ Schluesener and Z Zhang. (2011). Aptamers: selection, modification and application to nervous system diseases. Curr Med Chem. 18:4159-4168
14. Adler A, N Forster, M Homann and HU Göringer. (2008). Post-SELEX chemical optimization of a trypanosomespecific RNA aptamer. Comb Chem High T Scr 11:16-23.
15. Hicke BJ, AW Stephens, T Gould, Y Chang, CK Lynott, J Heil, S Borkowski, C Hilger, G Cook, S Warren and PG Schmidt. (2006). Tumor targeting by an aptamer. J Nucl Med 47:668-678.
16. Cheng C, YH Chen, KA Lennox, MA Behlke and BL Davidson. (2013). In vivo SELEX for identification of brain-penetrating aptamers. Mol Ther Nucleic Acids 2:e67.
17. de Lange EC. (2013). The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics and therapeutic effects. Fluids Barriers CNS 10:12
18. Healy JM, SD Lewis, M Kurz, RM Boomer, KM Thompson, C Wilson, TG McCauley. (2004). Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm Res 21:2234-2246.
19. Alyautdin R, I Khalin, MI Nafeeza, MH Haron, D Kuznetsov. (2014). Nanoscale drug delivery systems and the blood-brain barrier. Int J Nanomedicine 9:795-811.
20. Hwang SR and K Kim. (2014). Nano-enabled delivery systems across the blood-brain barrier. Arch Pharm Res 37:24-30.
21. Kaeser PS and WG Regehr. (2014). Molecular mechanisms for synchronous, asynchronous, and spontaneous neurotransmitter release. Annu Rev Physiol 76:333-363.
22. Bisaglia M, R Filograna, M Beltramini and L Bubacco. (2014). Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease. Ageing Res Rev 13: 107-114.
23. Abraham AD, KA Neve and M Lattal. (2014). Dopamine and extinction: A convergence of theory with fear and reward circuitry. Neurobiol Learn Mem 108:65-77.
24. Seeman MV and P Seeman. (2014). Is schizophrenia a dopamine supersensitivity psychotic reaction? Prog Neuropsychopharmacol Biol Psychiatry 48:155-160.
25. Trifilieff P and D Martinez. (2014). Imaging addiction: D2 receptors and dopamine signaling in the striatum as biomarkers for impulsivity. Neuropharmacology 76:498-509.
26. André VM, C Cepeda and MS Levine. (2010). Dopamine and glutamate in Huntington's disease: a balancing act. CNS Neurosci Ther 16:163-178.
27. Buse J, K Schoenefeld, A Münchau and V Roessner. (2013). Neuromodulation in tourette syndrome: dopamine and beyond. Neurosci Biobehav Rev 37:1069-1084.
28. Vaughan RA and JD Foster. (2013). Mechanisms of dopamine transporter regulation in normal and disease states. Trends Pharmacol Sci 34:489-496.
29. Mannironi C, A Di Nardo, P Fruscoloni and GP Tocchini-Valentini. (1997). In vitro selection of dopamine RNA ligands. Biochemistry 36:9726-9734.
30. Walsh R and MC DeRosa. (2009). Retention of function in the DNA homolog of the RNA dopamine aptamer. Biochem Biophys Res Commun 388:732-735.
31. Zheng Y, Y Wang and X Yang. (2011). Aptamer-based colorimetric biosensing of dopamine using unmodified gold nanoparticles. Sens Actuators B Chem 156:95-99.
32. Park H and IR Paeng. (2011). Development of direct competitive enzyme-linked aptamer assay for determination of dopamine in serum. Anal Chim Acta 685:65-73.
33. Kim E and IN Paeng. (2014). Advantageous sensitivity in the DNA homolog of the RNA dopamine aptamer. J Immunoassay Immunochem 35:83-100.
34. Liu S, X Xing, J Yu, W Lian, J Li, M Cui and J Huang. (2012). A novel label-free electrochemical aptasensor based on grapheme-polyaniline composite film for dopamine determination. Biosens Bioelectron 36:186-191.
35. Farjami E, R Campos, JS Nielsen, KV Gothelf, J Kjems and EE Ferapontova. (2013). RNA aptamer-based electrochemical biosensor for selective and label-free analysis of dopamine. Anal Chem 85:121-128.
36. Jiao L, G Lu, C Zhang, Y Yuan, J Wang, Q Zhang and P Li. (2013). Aptamer and graphene-based electrochemical biosensor for dopamine determination with high sensitivity and selectivity. Micro Nano Lett 8:903-905.
37. Li BR, YJ Hsieh, YX Chen, YT Chung, CY Pan and YT Chen. (2013). An ultrasensitive nanowire-transistor biosensor for detecting dopamine release from living PC12 cells under hypoxic stimulation. J Am Chem Soc 135: 16034-16037.
38. Holahan MR, MJ Clarke and DD Hines. (2010). Dopamine-mediated mk-801-induced elevation in food-based extinction responding in rats and associated changes in region-specific phosphorylated ERK. Psychopharmacology (Berl) 212:393-403.
39. Holahan MR, D Madularu, EM McConnell, R Walsh and MC DeRosa. (2011). Intra-accumbens injection of a dopamine aptamer abates mk-801-induced cognitive dysfunction in a model of schizophrenia. PLoS One 6:e22239.
40. Bruno JG, MP Carrillo, T Phillips and B King. (2008). Development of DNA aptamers for cytochemical detection of acetylcholine. In Vitro Cell Dev Biol Anim 44:63-72.
41. Huizenga DE and JW Szostak. (1995). A DNA aptamer that binds adenosine and ATP Biochemistry 34:656-665.
42. Chen SJ, YF Huang, CC Huang, KH Lee, ZH Lin and HT Chang. (2008). Colorimetric determination of urinary adenosine using aptamer-modified gold nanoparticles. Biosens Bioelectron 23:1749-1753.
43. Wang J, P Zhang, JY Li, LQ Chen, CZ Huang and YF Li. (2010). Adenosine-aptamer recognition-induced assembly of gold nanorods and a highly sensitive plasmon resonance coupling assay of adenosine in the brain of model SD rat. Analyst 135:2826-2831.
44. Bruno JG, A Richarte and T Phillips. (2014). Preliminary development of a DNA aptamer-magnetic bead capture electrochemiluminescence sandwich assay for brain natriuretic peptide. Microchem J 115:32-38.
45. Zhu J, J Wang, ZC Su, Q Li, MS Cheng and JH Zhang. (2008). Identification of ssDNA aptamers specific for antineuroexcitation peptide iii and molecular modeling studies: insights into structural interactions. Arch Pharm Res 31:1120-1128.
46. Mendonsa SD and MT Bowser. (2005). In vitro selection of aptamers with affinity for neuropeptide Y using capillary electrophoresis. J Am Chem Soc 127:9382-9383.
47. Tokunaga T, S Namiki, K Yamada, T Imaishi, H Nonaka, K Hirose and S Sando. (2012). Cell surface-anchored fluorescent aptamer sensor enables imaging of chemical transmitter dynamics. J Am Chem Soc 134:9561-9564.
48. Handy SM, BJ Yakes, JA DeGrasse, K Campbell, CT Elliott, KM Kanyuck and SL Degrasse. (2012). First report of the use of sazitoxin-protein conjugate to develop a DNA aptamer to a small molecule toxin. Toxicon 61:30-37.
49. C ? apek P and TJ Dickerson. (2010). Sensing the deadliest toxin: technologies for botulinum neurotoxin detection. Toxins (Basel) 2:24-53.
50. Tok JB and NO Fischer. (2008). Single microbead SELEX for efficient ssDNA aptamer generation against botulinum neurotoxin. Chem Commun (Camb) 16:1883-1885.
51. Fan M, SR McBurnett, CJ Andrews, AM Allman, JG Bruno and JL Kiel. (2008). Aptamer selection express: a novel method for rapid single-step selection and sensing of aptamers. J Biomol Tech 19:311-321.
52. Chang TW, M Blank, P Janardhanan, BR Singh, C Mello, M Blind and S Cai. (2010). In vitro selection of RNA aptamers that inhibit the activity of type A botulinum neurotoxin. Biochem Biophys Res Commun 396:854-860.
53. Bruno JG, AM Richarte, MP Carrillo and A Edge. (2012). An aptamer beacon responsive to botulinum toxins. Biosens Bioelectron 31:240-243.
54. Wei F and CM Ho. (2009). Aptamer-based electrochemical biosensor for Botulinum neurotoxin. Anal Bioanal Chem 393:1943-1948.
55. Wei F, B Bai and CM Ho. (2011). Rapidly optimizing an aptamer based BoNT sensor by feedback system control (FSC) scheme. Biosens Bioelectron 30:174-179.
56. Janardhanan P, CM Mello, BR Singh, J Lou, JD Marks and S Cai. (2013). RNA aptasensor for the rapid detection of natively folded type A botulinum neurotoxin. Talanta 117:273-280.
57. Nastasijevic B, BR Wright, J Smestad, AE Warrington, M Rodriguez and LJM Maher. (2012) Remyelination induced by a DNA aptamer in a mouse model of multiple sclerosis. PLOS One 7: e39595
58. Burmeister PE, C Wang, JR Killough, SD Lewis, LR Horwitz, A Ferguson, KM Thompson, PS Pendergrast, TG McCauley, M Kurz, J Diener, ST Cload, C Wilson and AD Keefe. (2006). 2-deoxy purine, 2-O-methyl pyrimidine (dRmY) aptamers as candidate therapeutics. Oligonucleotides 16:337-351.
59. Vorobjeva MA, VV Krasitskaya, AA Fokina, VV Timoshenko, GA Nevinsky, AG Venyaminova and LA Frank. (2014). RNA aptamer against autoantibodies associated with multiple sclerosis and bioluminescent detection probe on its basis. Anal Chem 86:2590-2594.
60. Tyler JY, XM Xu and JX Cheng. (2013) Nanomedicine for treating spinal cord injury. Nanoscale 5:8821-8836.
61. Wang Y, ZZ Khaing, N Li, B Hall, CE Schmidt and AD Ellington. (2010). Aptamer antagonists of myelin-derived inhibitors promote axon growth. PLOS One 5:e9726
62. Kalladka D and KW Muir. (2014). Brain repair: cell therapy in stroke. Stem Cells Cloning 7:31-44.
63. Blake CM, H Wang, DT Laskowitz and BA Sullenger. (2011). A reversible aptamer improves outcome and safety in murine models of stroke and hemorrhage. Oligonucleotides. 21:11-19.
64. Mayer G, F Rohrbach, B Pötzsch and J Müller. (2011). Aptamer-based modulation of blood coagulation. Hä-mostaseologie 4:258-263.
65. Rusconi CP, E Scardino, J Layzer, GA Pitoc, TL Ortel, D Monroe and BA Sullenger. (2002). RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419: 90-94.
66. Diener JL, HAD Lagassé, D Duerschmied, Y Merki, JF Tanguy, R Hutabarat, J Gilbert, DD Wagner and R Schaub. (2009). Inhibition of von Willebrand factormediated platelet activation and thrombosis by the antivon Willebrand factor A1-domain aptamer ARC1779. J Thromb Haemost 7:1155-1162.
67. Bae ON. (2012). Targeting von Willebrand Factor as a novel anti-platelet therapy; application of ARC1779, an anti-vWF aptamer, against thrombotic risk. Arch Pharm Res 35:1693-1699.
68. Markus HS, C McCollum, C Imray, MA Goulder, J Gilbert and A King. (2011). The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy a randomized trial. Stroke 42:2149-2153.
69. Denekas T, M Tröltzsch, A Vater, S Klussmann and K Messlinger. (2006). Inhibition of stimulated meningeal blood flow by a calcitonin gene-related peptide binding mirror-image RNA oligonucleotide. Br J Pharmacol 148: 536-543.
70. Vater A, F Jarosch, K Buchner and S Klussmann. (2003). Short bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach: tailored-SELEX. Nucleic Acids Res 31:e130.
71. Amiri H, K Saeidi, P Borhani, A Manafirad, M Ghavami and V Zerbi. (2013). Alzheimer's disease: pathophysiology and applications of magnetic nanoparticles as mri theranostic agents. ACS Chem Neurosci 4:1417-1429.
72. Tannenberg RK, HA Shamaileh, LH Lauridsen, JR Kanwar, PR Dodd and RN Veedu. (2013). Nucleic acid aptamers as novel class of therapeutics to mitigate Alzheimer's disease pathology. Curr Alzheimer Res 10: 442-448.
73. Rahimi F, K Murakami, JL Summers, CH Chen, and G Bitan. (2009). RNA aptamers generated against oligomeric Ab40 recognize common amyloid aptatopes with low specificiy but high sensitivity. PLoS ONE 4:e7694.
74. Ylera F, R Lurz, VA Erdmann and JP Furste. (2002). Selection of RNA aptamers to the alzehimer's disease amyloid peptide. Biochem Biophys Res Commun 290: 1583-1588.
75. Takahashi T, K Tada and H Mihara. (2009). RNA aptamers selected against amyloid b-peptide (Ab) inhibit the aggregation of Ab. Mol Biosyst 5:986-991.
76. Mathew A, A Aravind, D Brahatheeswaran, T Fukuda, Y Nagaoka, T Hasumura, S Iwai, H Morimotot, Y Yoshida, et al. (2012). Amyloid-binding aptamer conjugated curcumin-plga nanoparticle for potential use in Alzheimer's disease. BioNanoSci 2:83-93.
77. Bunka DHJ, BJ Mantle, IJ Morten, GA Tennent, SE Radford and PG Stockley (2007). Production and characterization of RNA aptamers specific for amyloid fibril epitopes. J Biol Chem 282:34500-34509.
78. Rentmeister A, A Bill, T Wahle, J Walter and M Famulok. (2006). RNA aptamers selectively modulate protein recruitment to the cytoplasmic domain of b-secretase BACE1 in vitro. RNA 12:1650-1660.
79. Ozawa D, T Nakamura, M Koike, K Hirano, Y Miki and M Beppu. (2013). Shuttling protein nucleolin is a microglia receptor for amyloid beta peptide 1-42. Biol Pharm Bull 36:1587-1593.
80. Ireson CR and LR Kelland. (2006). Discovery and development of anticancer aptamers. Mol Cancer Ther 5: 2957-2962.
81. Lollo B, F Steele and L Gold. (2014). Beyond antibodies: New affinity reagents to unlock the proteome. Proteomics 14:638-644.
82. Kiddle SJ, M Sattlecker, P Proitsi, A Simmons, E Westman, C Bazenet, SK Nelson, S Williams, A Hodges, C Johnston, H Soininen, I Kloszewska, P Mecocci, M Tsolaki, B Vellas, S Newhouse, S Lovestone and RJB Dobson. (2014). Alzheimer's disease onset and progression: a systematic review and replication study. J Alzheimers Dis 38:515-531.
83. Gupta S, M Hirota, SM Waugh, I Murakami, T Suzuki, M Muraguchi, M Shibamori, Y Ishikawa, TC Jarvis, et al. (2014) Chemically-modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor. J Biol Chem 289:8706-8719
84. Baird GS, SK Nelson, TR Keeney, A Stewart, S Williams, S Kraemer, ER Peskind and TJ Montine. (2012) Agedependent changes in the cerebrospinal fluid proteome by slow-off-rate modified aptamer array. Am J Pathol 180: 446-456.
85. Farrar CT, CM William, E Hurdy, T Hashimoto and BT Hyman. (2014). RNA aptamer probes as optical imaging agents for the detection of amyloid plaques. PLoS ONE 9:e89901.
86. Tsukakoshi K, R Harada, K Sode and K Ikebukuro. (2010). Screening of DNA aptamer which binds to a-synuclein. Biotechnol Lett 32:643-648.
87. Tsukakoshi K, K Abe, K Sode and K Ikebukuro. (2012). Selection of DNA aptamers that recognize a-synuclein oligomers using a competitive screening method. Anal Chem 84:5542-5547.
88. Aguzzi A and J Falsig. (2012). Prion propagation, toxicity and degradation. Nat Neurosci 15:936-939.
89. Boese AS, A Majer, R Saba and SA Booth. (2013). Small RNA drugs for prion disease: a new frontier. Expert Opin Drug Discov 8:1265-1284.
90. Gilch S and HM Schätzl. (2009). Aptamers against prion proteins and prions. Cell Mol Life Sci 66:2445-2455.
91. Praseetha PK, ST Anand, P Venugopalan and SC Murthy. (2012). Molecular nanobiotechnological approaches for the detection and therapy of prion related diseases. Nano Biomed Eng 4:50-57.
92. Yang Y, D Yang, HJ Schluesener and Z Zhang. (2007). Advances in SELEX and application of aptamers in the central nervous system. Biomol Eng 24:583-592.
93. Ogasawara D, H Hasegawa, K Kaneko, K Sode and K Ikebukuro. (2007). Screening of DNA aptamer against mouse prion protein by competitive selection. Prion 1: 248-254.
94. Murakami K, F Nishikawa, K Noda, T Yokoyama and S Nishikawa. (2008). Anti-bovine prion protein RNA aptamer containing tandem GGA repeat interacts both with recombinant bovine prion protein and its b isoform with high affinity. Prion 2:73-80.
95. Mashima T, A Matsugami, F Nishikawa, S Nishikawa and M Katahira. (2009). Unique quadruplex structure and interaction of an RNA aptamer against bovine prion protein. Nucleic Acids Res 37:6249-6258.
96. Bibby DF, AC Gill, L Kirby, CF Farquhar, ME Bruce and JA Garson. (2008). Application of a novel in vitro selection technique to isolate and characterize high affinity DNA aptamers binding mammalian prion proteins. J Virol Methods 151:107-115.
97. Rhie A, L Kirby, N Sayer, R Wellesley, P Disterer, I Sylvester, A Gill, J Hope, W James and A Tahiri-Alaoui. (2003). Characterization of 2-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion. J Biol Chem 278: 39697-39705.
98. Takemura K, P Wang, I Vorberg, W Surewicz, SA Priola, A Kanthasamy, R Pottathil, SG Chen and S Sreevatsan. (2006). DNA aptamers that bind to PrP(C) and not PrP(Sc) show sequence and structure specificity. Exp Biol Med (Maywood) 231:204-214.
99. Sayer, N. M. , Cubin, M. , Rhie, A. , Bullock, M. , Tahiri-Alaoui, A. , and James, W. (2004). Structural determinants of conformationally selective, prion-binding aptamers. J Biol Chem 279:13102-13109.
100. Kouassi GK, P Wang, S Sreevatan and J Irudayaraj. (2007). Aptamer-mediated magnetic nanoparticles as detection assay for prion protein assessment. Biotechnol Prog 23:1239-1244.
101. Xiao SJ, PP Hu, YF Li, CZ Huang, T Huang and GF Xiao. (2009). Aptamer-mediated turn-on fluorescence assay for prion protein based on guanine quenched fluophor. Talanta 79:1283-1286.
102. Hossain MT, T Shibata, T Kabashima and M Kai. (2010). Aptamer-Mediated Chemiluminescence Detection of Prion Protein on Membrane using Trimethoxyphenylglyoxal. Anal Sci 26:645-647.
103. Xiao SJ, PP Hu, XD Wu, YL Zou, LQ Chen, L Peng, J Ling, SJ Zhen, L Zhan, YF Li and CZ Huang. (2010). Sensitive discrimination and detection of prion diseaseassociated isoform with a dual-aptamer strategy by developing a sandwich structure of magnetic microparticles and quantum dots. Anal Chem 82:9736-9742.
104. Xiao SJ, PP Hu, GF Xiao, Y Wang, Y Liu and CZ Huang. (2012). Label-free detection of prion protein with its DNA aptamer through the formation of T-Hg2+-T configuration. J Phys Chem B 116:9565-9569.
105. Zhan L, L Peng, Y Yu, SJ Zhen and CZ Huang. (2012). Sensitive spectrofluorometry of cellular prion protein based on the on-off interaction between fluorescent dyelabelled aptamers and multi-walled carbon nanotubes. Analyst 137:4968-4973.
106. Hu PP, LL Zheng, L Zhan, JY Li, SJ Zhen, H Liu, LF Luo, GF Xiao and CZ Huang. (2013). Metal-enhanced fluorescence of nano-core-shell structure used for sensitive detection of prion protein with a dual-aptamer strategy. Anal Chim Acta 787:239-245.
107. Miodek A, A Poturnayová, M S ? nejdárková, T Hianik and H Korri-Youssoufi. (2013). Binding kinetics of human cellular prion detection by DNA aptamers immobilized on a conducting polypyrrole. Anal Bioanal Chem 405:2505-2514.
108. Miodek A, G Castillo, T Hianik and H Korri-Youssoufi. (2013). Electrochemical aptasensor of human cellular prion based on multiwalled carbon nanotubes modified with dendrimers: a platform for connecting redox markers and aptamers. Anal Chem 85:7704-7712.
109. Xiao SJ, PP Hu, LQ Chen, SJ Zhen, L Peng, YF Li and Z HUANG. (2013). A visual dual-aptamer logic gate for sensitive discrimination of prion diseases-associated isoform with reusable magnetic microparticles and fluorescence quantum dots. PLoS ONE 8:e53935.
110. Zhan L, LJ Liang, SJ Zhen, CM Li and CZ Huang. (2013). Aptamer-based spectrofluorometry for cellular prion protein using N,N-bis[3,3-(dimethylamino)propylamine]-3,4,9,10-perylenetetracarboxylic diimide. Analyst 138: 825-830.
111. Zhen SJ, HL Zhuang, J Wang and CZ Huang. (2013). Dual-aptamer-based sensitive and selective detection of prion protein through the fluorescence resonance energy transfer between quantum dots and grapheme oxide. Anal Methods 5:6904-6907.
112. Zhou YW, CM Li, Y Liu and CZ Huang. (2013). Effective detection and cell imaging of prion protein with new prepared targetable yellow-emission silver nanoclusters. Analyst 138:873-878.
113. Zhuang HL, SJ Zhen, J Wang and CZ Huang. (2013). Sensitive detection of prion protein through long range resonance energy transfer between grapheme oxide and molecular aptamer beacon. Anal Methods 5:208-212.
114. Miodek A, G Castillo, T Hianik and H Korri-Youssoufi. (2014). Electrochemical aptasensor of cellular prion protein based on modified polypyrrole with redox dendrimers. Biosens Bioelectron 56:104-111.
115. Chen LQ, SJ Xiao, PP Hu, L Peng, J Ma, LF Luo, YF Li and CZ Huang. (2012). Aptamer-mediated nanoparticlebased protein labeling platform for intracellular imaging and tracking endocytosis dynamics. Anal Chem 84:3099-3110.
116. Mashima T, F Nishkawa, YO Kamatari, H Fujiwara, M Saimura, T Nagata, T Kodaki, S Nishikawa, K Kuwata and M Katahira. (2013). Anti-prion activity of an RNA aptamer and its structural basis. Nucleic Acids Res 41: 1355-1362.
117. Blank M, T Weinschenk, M Priemer and H Schluesener. (2001). Systemic evolution of dna aptamer binding to rat brain tumor microvessels. Selective targeting of endothelial regulatory protein pigpen. J Biol Chem 276:16464-16468.
118. Cerchia L, F Duconge, C Pestourie, J Boulay, Y Aissouni, K Gombert, B Tavitian, V de Franciscis and D Libri. (2005). Neutralizing aptamers from whole-cell SELEX inhibit the ret receptor tyrosine kinsase. PLoS Biol 3:e123.
119. Daniels DA, H Chen, BJ Hicke, KM Swiderek and L Gold. (2003). A tenascin-C aptamer identified by tumor cell SELEX: systemic evolution of ligands by exponential enrichment. Proc Natl Acad Sci USA 100:15416-15421.
120. Hicke BJ, C Marion, YF Chang, T Gould, CK Lynott, D Parma, PG Schmidt and S Warren. (2001). Tenascin-C Aptamers are generated using tumor cells and purified protein. J Biol Chem 276:48644-48654.
121. de Franciscis V, CL Esposito, S Catuogno, L Cellai and L Cerchia. (2009). Aptamers as innovative diagnostic and therapeutic agents in the central nervous system. CNS Neurol Disord Drug Targets 8:393-401.
122. Kang D, J Wang, W Zhang, Y Song, X Li, Y Zou, M Zhu, Z Zhu, F Chen and CJ Yang. (2012). Selection of DNA aptamers against glioblastoma cells with high affinity and specificity. PLoS ONE 7:e42731.
123. Bayrac AT, K Sefah, P Parekh, C Bayrac, B Gulbakan, HA Oktem and W Tan. (2011). In vitro selection of DNA aptamers to glioblastoma multiforme. ACS Chem Neurosci 2:175-181.
124. Cerchia L, CL Esposito, AH Jacobs, B Tavitian and V de Franciscis. (2009). Differential SELEX in human glioma cell lines. PLoS ONE 4:e7971.
125. Kim Y, Q Wu, P Hamerlik, M Hitomi, AE Sloan, GH Barnett, RJ Weil, P Leahy, AB Hjelmeland and JN Rich. (2013). Aptamer identification of brain tumor-initiating cells. Cancer Res 73:4923-4936.
126. Da Rocha Gomes S, J Miguel, L Azéma, S Eimer, C Ries, E Dausse, H Loiseau, M Allard and JJ Toulmé. (2012). 99mTc-MAG3-Aptamer for imaging human tumors associated with high level of matrix metalloprotease-9. Bioconjug Chem 23:2192-2200.
127. Cheng Y, RA Morshed, B Auffinger, AL Tobias and MS Lesniak. (2014). Multifunctional nanoparticles for brain tumor imaging and therapy. Adv Drug Deliv Rev 66: 42-57.
128. Hernández-Pedro NY, E Rangel-López, R Magana-Maldonado, VP de La Cruz, AS del Angel, B Pineda and J Sotelo. (2013). Application of nanoparticles on diagnosis and therapy in gliomas. Biomed Res Int 2013:351031.
129. Li Z, P Huang, R He, J Lin, S Yang, X Zhang, Q Ren and D Cui. (2010). Aptamer-conjugated dendrimer-modified quantum dots for cancer cell targeting and imaging. Mater Lett 64:375-378.
130. Li J and JJ Zhu. (2013). Quantum dots for fluorescent biosensing and bio-imaging applications. Analyst 138: 2506-2515.
131. Kim B, J Yang, M Hwang, J Choi, HQ Kim, E Jang, JH Lee, SH Ryu, JS Suh, YM Huh and S Haam. (2013). Aptamer-modified magnetic nanoprobe for molecular MR imaging of VEGFR2 on angiogenic vasculature. Nanoscale Res Lett 8:399-409.
132. Nair BG, Y Nagaoka, H Morimoto, Y Yoshida, T Maekawa and DS Kumar. (2010). Aptamer conjugated magnetic nanoparticles as nanosurgeons. Nanotechnology 21: 455102.
133. Liu Y, C Kuan, J Mi, X Zhang, BM Clary, DD Bigner and BA Sullenger. (2009). Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis. Biol Chem 390:137-144.
134. Bechet D, SR Mordon, F Guillemin and MA Barberi-Heyob. (2012). Photodynamic therapy of malignant brain tumors: a complementary approach to conventional therapies. Cancer Treat Rev 40:229-241.
135. Kruspe S, C Meyer and U Hahn. (2014). Chlorin e6 conjugated interleukin-6 receptor aptamers selectively kill target cells upon irradiation. Mol Ther Nucleic Acids 3:e143.
136. Kudo M, H Jono, S Shinriki, S Yano, H Nakamura, K Makino, T Hide, D Muta, M Ueda, et al. (2009). Antitumor effect of humanized anti-interleukin-6 receptor antibody (tocilizumab) on glioma cell proliferation. Laboratory investigation. J Neurosurg 111:219-225.
137. Guo J, X Gao, L Su, H Xia, G Gu, Z Pang, X Jiang, L Yao, J Chen and H Chen. (2011). Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 32:8010-8020.
138. Gao H, J Qian, Z Yang, Z Pang, Z Xi, S Cao, Y Wang, S Pan, S Zhang, et al. (2012) Whole-cell SELEX aptamerfunctionalised poly(ethyleneglycol)-poly(e-caprolactone) nanoparticles for enhanced targeted glioblastoma therapy. Biomaterials 33:6264-6272.
139. Chen H, X Zheng, B Di, D Wang, Y Zhang, H Xia and Q Mao. (2013). Aptamer modification improves adenoviral transduction of malignant glioma cells. J Biotechnol 168: 326-366.
140. Huse JT and EC Holland. (2010). Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10:319-331.
141. Gao H, J Qian, S Cao, Z Yang, Z Pang, S Pan, L Fan, Z Xi, X Jiang and Q Zhang. (2012). Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials 33:5115-5123.
142. Li J, L Feng, L Fan, Y Zha, L Guo, Q Zhang, J Chen, Z Pang, Y Wang, et al. (2011). Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 32:4943-4950.
143. Chen CH, KR Dellamaggiore, CP Ouellette, CD Sedano, M Lizadjohry, GA Chernis, M Gonzales, FE Baltasar, AL Fan, et al. (2008). Aptamer-based endocytosis of lysosomal enzyme. Proc Natl Acad Sci (USA) 105:15908-15913.
144. Porciani D, G Signore, L Marchetti, P Mereghetti, R Nifosi and F Beltram. (2014). Two interconvertible folds modulate the activity of a DNA aptamer against transferrin receptor. Mol Ther Nucleic Acids 3:e144.
145. Mu C, N Dave, J Hu, P Desai, G Pauletti, S Bai and J Hao. (2013). Solubilization of flurbiprofen into aptamermodified PEG-PLA micelles for targeted delivery to brain-derived endothelial cells in vitro. J Microencapsul 30:701-708.
146. Wilner SE, B Wengerter, K Maier, M de Lourdes Borba Magalhaes, DS Del Amo, S Pai, F Opazo, SO Rizzoli, A Yan and M Levy. (2012). An RNA alternative to human transferrin: a new tool for targeting human cells. Mol Ther Nucleic Acids 1:e21.
147. Huang Z, W Pei, S Jayaseelan, H Shi and L Niu. (2007). RNA aptamers selected against the GluR2 glutamate receptor channel. Biochemistry 46:12648-12655.
148. Du M, H Ulrich, X Zhao, J Aronowski, V Jayaraman. (2007). Water soluble RNA based antagonist of AMPA receptors. Neuropharmacology 53:242-251.
149. Liu Y, Q Sun, Q Chen, TH Lee, Y Huang, WC Wetsel, GA Michelotti, BA Sullenger and X Zhang. (2009). Targeting inhibition of GluR1 Ser845 phosphorylation with an RNA aptamer that blocks AMPA receptor trafficking. J Neurochem 108:147-157.
150. Ulrich H, JE Ippolito, OR Pagán, VA Eterović, RM Hann, H Shi, JT Lis, ME Eldefrawi and G Hess. (1998). In vitro selection of RNA molecules that displace cocaine from the membrane-bound nicotinic acetylcholine receptor. Proc Natl Acad Sci USA 95:14051-14056.
151. Hess GP, H Ulrich, H Breitinger, L Niu, AM Gamerio, C Grewer, S Srivastava, JE Ippolito, SM Lee, V Jayaraman and SE Coombs. (2000). Mechanism-based discovery of ligands that counteract inhibition of the nicotinic acetylcholine receptor by cocaine and MK-801. Proc Natl Acad Sci (USA) 97:13895-13900.
152. Sivaprakasam K, OR Pagán and GP Hess. (2010). Minimal RNA aptamer sequences that can inhibit or alleviate noncompetitive inhibition of muscle-type nicotinic acetylcholine receptor. J Membr Biol 233:1-12.
153. Cui Y, H Ulrich and GP Hess. (2004). Selection of 2-fluoro-modified RNA aptamers for alleviation of cocaine and mk-801 inhibition of the nicotinic acetylcholine receptor. J Membr Biol 202:137-149.
154. Krivoshein AV and GP Hess. (2004). Mechanism-based approach to the successful prevention of cocaine inhibition of the neuronal (a3b4) nicotinic acetylcholine receptor. Biochemistry 43:481-489.
155. Cui Y, P Rajaesthupathy and GP Hess. (2004). Selection of stable RNA molecules that can regulate the channel-opening equilibrium of the membrane-bound g-aminobutyric acid receptor. Biochemistry 43:16442-16449.
156. Huang YZ, FJ Hernandez, B Gu, KR Stockdale, K Nanapaneni, TE Scheetz, MA Behlke, AS Peek, T Bair, PH Giangrande and JO McNamara. (2012). RNA aptamer-based functional ligands of the neurotrophin receptor, TrkB. Mol Pharmacol 82:623-635.
157. Gao X and C Li. (2014). Nanoprobes visualizing gliomas by crossing the blood brain tumor barrier. Small 10:426-440.
158. Bertelson JA and B Ajtai. (2014). Neuroimaging of dementia. Neurol Clin 32:59-93.
159. Scheck AC and P Stafford. (2012). Design and use of biomarkers for the current and future clinical management of brain tumors. Biomark Med 6:293-295.
160. El-Jawahri A, D Patel, M Zhang, N Mladkova and A Chakravarti. (2008). Biomarkers of clinical responsiveness in brain tumor patients: progress and potential. Mol Diagn Ther 12:199-208.
161. Marciniuk K, R Taschuk and S Napper. (2013). Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapy. Clin Dev Immunol 2013:473706.
162. Berezovski MV, M Lechmann, MU Musheev, TW Mak and SN Krylov. (2008). Aptamer-facilitated biomarker discovery (AptaBiD). J Am Chem Soc 130:9137-9143.
163. Schaeffer E and A Duplantier. (2010) Glutamate and neurodegenerative disease. Top Med Chem 6:91-147.
164. Brady RO Jr, JM McCarthy, AP Prescot, JE Jensen, AJ Copper, BM Cohen, PF Renshaw and D Ö ngür. (2013) Brain gamma-aminobutyric acid (GABA) abnormalities in bipolar disorder. Bipolar Disord 15:434-439.
165. Murphy DL, PR Moya, MA Fox, LM Rubenstein, JR Wendland and KR Timpano. (2013) Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive-compulsive disorder as an example of overlapping clinical and genetic heterogeneity. Philos Trans R Soc Lond B Biol Sci 368: 20120435.